<DOC>
	<DOCNO>NCT00914472</DOCNO>
	<brief_summary>Investigate , randomize , open , parallel comparative , non-inferiority heparin sodium produce laboratory Hipolabor compare heparin manufacture APP patient hemodialysis due renal failure , control hemostasis , verify formation clot ( fibrin ) hemodialysis system pharmacodynamic parameter ( TTPA Anti-Xa ) use heparin</brief_summary>
	<brief_title>Comparison Two Heparin Formulations Patients With Chronic Renal Failure .</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . Research patient agree participate sign write informed consent ; 2 . Patients age 18 year , sex , regardless color social class ; 3 . Patients impaired renal function chronic hemodialysis schedule least 3 time week give use heparin prophylaxis thrombosis system . 1 . Hypersensitivity heparin sodium / benzyl alcohol ; 2 . History bleed disease change blood coagulation could aggravate terminate clinical manifestation , table active peptic gastric ulcer ; 3 . Severe liver disease ; 4 . Cancer ; 5 . Period gestation ; 6 . Genetic abnormality coagulation system ; 7 . Multiple trauma ; 8 . Use aspirin high dos ( 200mg per day ) ; 9 . Use glucocorticoid least 1 month ; 10 . Use anticoagulant ; 11 . Submission big surgery do less 15 day ; 12 . History persistent hypertension end dialysis 150/100 mmHg ; 13 . Indicated dos heparin 20 % 150UI/kg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Preventing thrombus formation</keyword>
</DOC>